Pilar Pizcueta

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

PPARγ activation by leriglitazone counteracts neurodegeneration and neuroinflammation in a disease-relevant mouse model of COASY dysfunction.

PPARγ activation by leriglitazone counteracts neurodegeneration and neuroinflammation in a disease-relevant mouse model of COASY dysfunction.

Journal: Pharmacological research
Published: December 23, 2025

Leriglitazone improves iron homeostasis and ferroptotic markers in frataxin-deficient dorsal root ganglia neurons.

Leriglitazone improves iron homeostasis and ferroptotic markers in frataxin-deficient dorsal root ganglia neurons.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 08, 2025

Safety and efficacy of leriglitazone in childhood cerebral adrenoleukodystrophy (NEXUS): an interim analysis of an open-label, phase 2/3 trial.

Safety and efficacy of leriglitazone in childhood cerebral adrenoleukodystrophy (NEXUS): an interim analysis of an open-label, phase 2/3 trial.

Journal: EClinicalMedicine
Published: January 20, 2025

Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models.

Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models.

Journal: Nature communications
Published: August 30, 2023

Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome.

Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome.

Journal: Journal of translational medicine
Published: July 13, 2023

Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate.

Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate.

Journal: International journal of molecular sciences
Published: November 29, 2022

PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes.

PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes.

Journal: Pharmaceutics
Published: November 21, 2022

Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.

Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.

Journal: The Lancet. Neurology
Published: May 06, 2022

Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children.

Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children.

Journal: CPT: pharmacometrics & systems pharmacology
Published: March 22, 2022

PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia.

PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia.

Journal: Neurobiology of disease
Published: August 06, 2020

The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy.

The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy.

Journal: Science translational medicine
Published: April 03, 2020

Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.

Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.

Journal: Bioorganic & medicinal chemistry letters
Published: April 16, 2012
Showing 1-12 of 13

Last Updated: 09/26/2026